scholarly journals Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment

2013 ◽  
Vol 1 (2) ◽  
pp. 385-389 ◽  
Author(s):  
VERONICA GOFFREDO ◽  
COSMO DAMIANO GADALETA ◽  
ANNAMARIA LATERZA ◽  
ANGELO VACCA ◽  
GIROLAMO RANIERI
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Levels ◽  
Response To Treatment ◽  
Predictive Role ◽  
Arterial Chemoembolization

scholarly journals Evolving Role of MRI in Assessment of Response of Hepatocellular Carcinoma Patients Post Trans-Arterial Chemoembolization: What Does the Physician Want to Know?

2021 ◽  
Vol 89 (6) ◽  
pp. 1017-1024
Author(s):  
MOHAMED F.H. ABDALLAH, M.D.; MOHAMED HOSNI K. ABDELMAKSOUD, M.D. ◽  
SHIMAA H.I. DESOUKY, M.D.; MONA HASSAN, M.D. ◽  
MEDHAT MADBOULY, M.D.
Keyword(s):  
Hepatocellular Carcinoma ◽  
Arterial Chemoembolization

Study of the role of transcatheter arterial chemoembolization using iodized oil with and without gel foam for the management of hepatocellular carcinoma

2015 ◽  
Vol 28 (2) ◽  
pp. 447
Author(s):  
AymanAbd El-Halim Mohammed El-Gamal ◽  
HanySaid Sabry ◽  
UsamaaLotfy El-Abd ◽  
GamalSaad El Deeb ◽  
AymanMohamed El-Lehleh
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Iodized Oil ◽  
Arterial Chemoembolization

Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC)

2014 ◽  
Vol 29 (8) ◽  
pp. 1637-1644 ◽  
Author(s):  
Caterina Pozzan ◽  
Romilda Cardin ◽  
Marika Piciocchi ◽  
Nora Cazzagon ◽  
Gemma Maddalo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Levels ◽  
Prognostic Role

scholarly journals The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis

2016 ◽  
Vol 7 (4) ◽  
pp. 615-623 ◽  
Author(s):  
Masayoshi Yada ◽  
Masayuki Miyazaki ◽  
Kenta Motomura ◽  
Akihide Masumoto ◽  
Makoto Nakamuta ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lactate Dehydrogenase ◽  
Liver Fibrosis ◽  
Serum Levels ◽  
Prognostic Role

Combination therapy with ipilimumab and electrochemotherapy: Preliminary efficacy results and correlation with immunologic parameters.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20031-e20031 ◽  
Author(s):  
Ester Simeone ◽  
Lucia Benedetto ◽  
Giusy Gentilcore ◽  
Corrado Caraco ◽  
Gianluca Di Monta ◽  
...  
Keyword(s):  
Survival Benefit ◽  
T Regulatory Cells ◽  
Mononuclear Cells ◽  
Stage Iv ◽  
Advanced Melanoma ◽  
Response To Treatment ◽  
Peripheral Blood Mononuclear ◽  
Predictive Role ◽  
Combination Approach

e20031 Background: Ipilimumab is the first agent approved for the treatment of advanced melanoma that showed a survival benefit in randomized phase 3 trials. Despite the survival benefit, due to its mechanism of action it is associated with a slow onset and low rate of responses and, in many cases, responses occur after other therapies, like chemotherapy, targeted therapy and radiotherapy. Electrochemotherapy (ECT) has been shown to be effective and well tolerated for local control of metastatic melanoma with superficial lesions. The current challenge is to improve ipilimumab efficacy by combination/sequence with other therapies. We performed a pilot study of combination with ipilimumab and ECT in order to verify the possible increase of response rate. Furthermore, due to the lack of predictive markers, we evaluated the possible predictive role of circulating T-regulatory cells (T-Reg) variations in peripheral blood mononuclear cells (PBMC) of treated patients. Methods: We collected data from 10 patients (pts) with advanced melanoma (6 stage IIIc and 4 stage IV M1c) treated with ipilimumab at 3 mg/kg every 3 weeks for 4 cycles (day 1) and ECT with bleomycine at 15 mg/m2 (day 2) on superficial lesions. Blood draws were collected on day 0, 1 and 2, then on day 15 and 30 from ECT, at each cycle of ipilimumab and at every tumor evaluation (every 12 weeks). PBMC were thawed and labeled with anti-CD4-Pe-Cy-5, CD25-Pe and anti-FoxP3-AlexaFlour488 for T-Reg. Results: 10/10 (100%) pts showed local objective responses (4 CR and 6 PR). 7/10 (70%) pts showed local response (6 PR and 1 CR) after the second ipilimumab dose and 3/10 showed response (3 CR) at week 12. Two pts with PR (28%) out of the group of 7 showed response on distant lesions at week 24 (abscopal effect). All pts are still alive with a median follow up of 11 months (range 6-18). We found in all pts a decrease of T-Reg of 0.10% (range 0.50-2.6%) per cycle and no variation of CD4+ and CD25+ lymphocytes. Conclusions: Our preliminary results show that a combination approach with ipilimumab and ECT may increase responses to ipilimumab. T-Reg decrease in PBMC could be associated with response to treatment. Further studies about this combination are warranted.

scholarly journals Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma

2015 ◽  
Vol 37 (1) ◽  
pp. 276-283 ◽  
Author(s):  
Liming Cui ◽  
Yue Hu ◽  
Bin Bai ◽  
Shide Zhang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Outcome ◽  
Molecular Marker ◽  
Treatment Response ◽  
Vascular Invasion ◽  
Healthy Controls ◽  
Lower Serum ◽  
Serum Microrna ◽  
Arterial Chemoembolization

Aim: To identify the role of serum MicroRNA-335 (miR-335) in determining the treatment response to Trans-arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and their prognosis after TACE. Methods: A total of 125 HCC patients were enrolled in this study. All these patients underwent TACE and the treatment response was evaluated. All patients were followed for prognosis analyses. Serum miR-335 levels immediate before and 30 days after TACE were determined. Results: HCC patients had significantly lower miR-335 levels than hepatitis patients and healthy controls. Lower serum miR-335 levels were closely associated with more progressive clinical features, including a higher mean serum AFP level, more vascular invasion, cirrhosis and larger tumor size. Response rates were higher in patients with high miR-335 compared to those with low miR-335 level. Patients with lower serum miR-335 levels had significantly poorer prognosis than patients with higher serum miR-335 levels. Conclusion: Our data suggest that serum miR-335 can be used as a molecular marker to predict the treatment response and clinical outcome in HCC patients receiving TACE.

scholarly journals Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Luca Faloppi ◽  
Maristella Bianconi ◽  
Riccardo Memeo ◽  
Andrea Casadei Gardini ◽  
Riccardo Giampieri ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lactic Dehydrogenase ◽  
Serum Levels ◽  
Clinical Results ◽  
Significant Prognostic Factor ◽  
Hypoxic Conditions ◽  
Potential Biomarker ◽  
Key Enzyme ◽  
Primary Liver Tumour

Hepatocellular carcinoma (HCC) is the most common primary liver tumour (80–90%) and represents more than 5.7% of all cancers. Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking. Lactic dehydrogenase (LDH) is a glycolytic key enzyme in the conversion of pyruvate to lactate under anaerobic conditions. In preclinical models, upregulation of LDH has been suggested to ensure both an efficient anaerobic/glycolytic metabolism and a reduced dependence on oxygen under hypoxic conditions in tumour cells. Data from several analyses on different tumour types seem to suggest that LDH levels may be a significant prognostic factor. The role of LDH in HCC has been investigated by different authors in heterogeneous populations of patients. It has been tested as a potential biomarker in retrospective, small, and nonfocused studies in patients undergoing surgery, transarterial chemoembolization (TACE), and systemic therapy. In the major part of these studies, high LDH serum levels seem to predict a poorer outcome. We have reviewed literature in this setting trying to resume basis for future studies validating the role of LDH in this disease.

scholarly journals Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Zhen-feng Zhu ◽  
Li-ping Zhuang ◽  
Chen-yue Zhang ◽  
Zhou-yu Ning ◽  
Dan Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio ◽  
Predictive Role

scholarly journals Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus Patients

Pathogens ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 57
Author(s):  
Momen Askoura ◽  
Hisham A. Abbas ◽  
Hadeel AlSadoun ◽  
Wesam H. Abdulaal ◽  
Amr S. Abu Lila ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Serum Level ◽  
Viral Infections ◽  
Serum Levels ◽  
Chronic Patients

Hepatitis C virus (HCV) is one of the most epidemic viral infections in the world. Three-quarters of individuals infected with HCV become chronic. As a consequence of persistent inflammation, a considerable percentage of chronic patients progress to liver fibrosis, cirrhosis, and finally hepatocellular carcinoma. Cytokines, which are particularly produced from T-helper cells, play a crucial role in immune protection against HCV and the progression of the disease as well. In this study, the role of interleukins IL-33, IL-17, and IL-25 in HCV patients and progression of disease from chronicity to hepatocellular carcinoma will be characterized in order to use them as biomarkers of disease progression. The serum levels of the tested interleukins were measured in patients suffering from chronic hepatitis C (CHC), hepatocellular carcinoma (HCC), and healthy controls (C), and their levels were correlated to the degree of liver fibrosis, liver fibrosis markers and viral load. In contrast to the IL-25 serum level, which increased in patients suffering from HCC only, the serum levels of both IL-33 and IL-17 increased significantly in those patients suffering from CHC and HCC. In addition, IL-33 serum level was found to increase by liver fibrosis progression and viral load, in contrast to both IL-17 and IL-25. Current results indicate a significant role of IL-33 in liver inflammation and fibrosis progress in CHC, whereas IL-17 and IL-25 may be used as biomarkers for the development of hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document